NCT00322569已完成3 期
A Randomized, Multi-Center Study of the Pimecrolimus-Eluting (Corio™) and Pimecrolimus/Paclitaxel-Eluting Coronary Stent System (SymBio™) in Patients With De Novo Lesions of the Native Coronary Arteries
适应症
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 246
- 试验地点
- 1
- 主要终点
- Primary angiographic late loss in the stent as measured by Quantitative Coronary Angiography (QCA)
研究概览
简要总结
To demonstrate non-inferiority in 6-month angiographic in-stent late lumen loss of the pimecrolimus-eluting coronary stent (Corio) compared to the CoStar coronary stent control arm and the dual pimecrolimus/paclitaxel-eluting (Symbio) coronary stent compared to the CoStar coronary stent control arm for the treatment of single de novo lesions <25 mm in length in native coronary arteries 2.5 - 3.5 mm in diameter.
详细描述
This study is designed to evaluate 6 month in-stent late lumen loss of the 1) Corio™ pimecrolimus-eluting coronary stent system and the 2) SymBio™ dual pimecrolimus/paclitaxel-eluting coronary stent system compared to the CoStar™ Paclitaxel-Eluting Coronary Stent System control arm.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •General Inclusion Criteria
- •Eligible for percutaneous coronary intervention (PCI).
- •Documented stable or unstable angina pectoris
- •Left ventricular ejection fraction (LVEF) ≥25%
- •Acceptable candidate for coronary artery bypass graft surgery (CABG).
- •Target lesion < 25 mm in length with RVD of ≥2.5 mm to ≤3.5 mm with visually estimated stenosis of ≥50% and < 100% .
- •Target vessel had not undergone prior revascularization within the preceding 6 months.
- •Target lesion must have been a minimum of 10 mm distance from any previously treated segment of the target vessel
- •Patient understood the study requirements and the treatment procedures and provided written Informed Consent, approved by the local Ethics Committee.
- •Willing to comply with all specified follow-up evaluations.
排除标准
- •General Exclusion Criteria
- •Known sensitivity to pimecrolimus, paclitaxel, the polymer (PLGA) or cobalt chromium.
- •Planned treatment with any other PCI device in the target vessel(s).
- •MI within 72 hours prior to the index procedure
- •The patient is in cardiogenic shock.
- •Cerebrovascular Accident (CVA) within the past 6 months.
- •Acute or chronic renal dysfunction
- •Contraindication to ASA or to clopidogrel.
- •Thrombocytopenia
- •Active gastrointestinal (GI) bleeding within the past 3 months.
- •Any prior true anaphylactiod reaction to contrast agents
- •Patient is currently taking colchicine, chronic systemic steroid therapy or systemic immunosuppressant therapy, or or had been treated with paclitaxel (systemic) within 12 months of the index procedure.
- •Patient was currently, or was on long term intermittent therapy with topical pimecrolimus
- •Female of childbearing potential.
- •Life expectancy of less than 24 months due to other medical conditions.
- •Co-morbid condition(s)
- •Currently participating in another investigational drug or device study
- •General Angiographic Exclusion Criteria:
- •Left main coronary artery disease (stenosis >50%), whether protected or unprotected.
- •Target lesion was ostial in location (within 3.0 mm of vessel origin).
- •Target lesion and/or target vessel proximal to the target lesion was severely calcified by visual estimation.
- •Target lesion involved a bifurcation with a diseased (>50% stenotic) branch vessel >2.0 mm in diameter that required intervention.
- •Target lesion was totally occluded Thrombolysis In MI (TIMI flow 0) or TIMI flow ≤
- •Angiographic presence of probable or definite thrombus.
- •Target vessel would have been pre-treated with an unapproved device, directional or rotational coronary atherectomy, laser, cutting balloon or transluminal extraction catheter immediately prior to stent placement.
- •Prior coronary intervention using brachytherapy to any segment of the target vessel.
- •The target vessel had prior drug-eluting stent placement to vessel segment (or branch) proximal to intended target lesion site within preceding 6 months.
- •Angiographic restenosis of any segment of the target vessel that had undergone prior percutaneous coronary intervention.
- •Angiographic evidence of atherosclerotic disease with >50% diameter stenosis (by visual estimate) proximal or distal to the target lesion (applies to the major epicardial portion of the target vessel and contiguous vessel segment if the target lesion was located in a branch vessel).
- •Prior surgical revascularization of the target vessel with patent graft (saphenous vein graft or arterial conduit).
- •Target lesion lied within 10mm of prior surgical anastomosis site.
研究组 & 干预措施
1
Experimental
Corio™ Pimecrolimus-Eluting Cobalt Chromium Coronary Stent System
干预措施: Corio™ Pimecrolimus-Eluting Coronary Stent System (Device)
2
Experimental
SymBio™ Pimecrolimus/Paclitaxel-Eluting Coronary Stent System
干预措施: SymBio™ Pimecrolimus/Paclitaxel-Eluting Coronary Stent System (Device)
Control Arm
Active Comparator
Costar ™ Paclitaxel-Eluting Coronary Stent System
干预措施: Costar ™ Paclitaxel-Eluting Coronary Stent System (Device)
结局指标
主要结局
Primary angiographic late loss in the stent as measured by Quantitative Coronary Angiography (QCA)
时间窗: 6 months post-procedure
次要结局
- MACE (composite of non-cardiac death, new Qw/nonQw MI, and TVR) as described below(30 days and 6 months)
- Primary Device Success defined as attainment of <50% in-stent residual stenosis of the target lesion using only the assigned device in the absence of device malfunction and device-related complication.(30 days and 6 months, 1, 2, 3, 4, and 5 years post-procedure)
- Lesion Success defined as attainment of <50% residual stenosis of the target lesion using the assigned study device or any percutaneous method.(30 days and 6 months, 1, 2, 3, 4, and 5 years post-procedure)
- Procedure Success defined as attainment of final lesion success in the absence of in-hospital MACE.(30 days and 6 months, 1, 2, 3, 4, and 5 years post-procedure)
- Angiographic in-stent and in-segment binary restenosis (≥50% diameter stenosis).(30 days and 6 months, 1, 2, 3, 4, and 5 years post-procedure)
- In-stent and in-segment MLD(6 months post-procedure)
- In-segment angiographic late loss(6 months post-procedure)
- Clinically driven Target Lesion Revascularization (TLR)(6 months post-procedure)
- Percent volume obstruction of the stent by intravascular ultrasound (IVUS) in the IVUS cohort.(6 months post-procedure)
- Incidence of late acquired incomplete stent to vessel apposition (stent malapposition) by IVUS in the IVUS cohort.(6 months post-procedure)
- Incidence of reported MACE(1, 2, 3, 4 and 5 years post-procedure)
- Comparison of the pimecrolimus-eluting stent to the pimecrolimus/paclitaxel-eluting stent for primary and secondary endpoints.(30 days and 6 months, 1, 2, 3, 4, and 5 years post-procedure)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
4 期
Comparison One vs Six Months of Dual Antiplatelet Therapy After Implanted Firehawk TM Stent in High Bleeding Risk Patients With Coronary Artery DiseaseCoronary DiseasePercutaneous Coronary InterventionDrug Eluting StentDual Antiplatelet TherapyNCT03287167Shanghai MicroPort Medical (Group) Co., Ltd.1,720
已完成
2 期
Safety and Efficacy of Pimecrolimus Ophthalmic Suspension in Patients With Moderate to Severe Keratoconjunctivitis SiccaKeratoconjunctivitis SiccaNCT00128245Novartis440
已完成
不适用
Artimes Pro Low Profile Dilatation Catheters for Pre-Dilatation in Patients With Symptomatic Ischemic Heart DiseaseHeart Disease, IschemicCoronary StenosisCoronary Artery DiseaseNCT03301246Eminence Clinical Research, Inc.60
终止
3 期
A Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic OintmentBlepharitisNCT06400511Famy Life Sciences, a Viatris Company477
已完成
2 期
Determination of Safe and Effective Dose of Romiplostim (AMG 531) in Subjects With Myelodysplastic Syndrome (MDS)Receiving Hypomethylating AgentsMDSThrombocytopeniaMyelodysplastic SyndromesNCT00321711Amgen69